Ignyta announces approval of an IDE for companion diagnostic assay to STARTRK-2 trial
Ignyta announced the FDA has approved an investigational device exemption for its RNA-based companion diagnostic, next-generation sequencing assay (Trailblaze Pharos™). The Trailblaze Pharos assay is intended for use in identifying patients who have solid tumors with NTRK1/2/3, ROS1. August 31, 2016